Controlling serogroup B invasive meningococcal disease: The Canadian perspective

Expert Review of Vaccines

Volumn 12, Issue 5, 2013, Pages 505-517

  Bettinger, Julie A ^a   Deeks, Shelley L ^b   Halperin, Scott A ^c   Tsang, Raymond ^d   Scheifele, David W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Canadian epidemiology; invasive meningococcal disease; meningococcal immunization strategies; serogroup B vaccines

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; LP 2086; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN A; PLACEBO; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; RECOMBINANT VACCINE; VACCINE;

ANTIBODY TITER; BORDETELLA PERTUSSIS; DIPHTHERIA; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HORIZONTAL GENE TRANSFER; HUMAN; IMMUNIZATION; INFECTION CONTROL; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MEASLES; MENINGOCOCCOSIS; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; MUMPS; NEISSERIA MENINGITIDIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; RUBELLA; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TETANUS; CANADA; EPIDEMIC MENINGITIS; GENETICS; HEALTH CARE POLICY; IMMUNOLOGY; METHODOLOGY; MICROBIOLOGY; PREVENTIVE HEALTH SERVICE; VACCINATION;

CANADA; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; VACCINATION; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 84877615423     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.30     Document Type: Review

References (98)

1. Parkinson AJ, Bruce MG, Zulz T. International Circumpolar Surveillance, an Arctic network for the surveillance of infectious diseases. Emerging Infect. Dis. 14(1), 18-24 (2008).
2. Scheifele DW. IMPACT after 17 years: lessons learned about successful networking. Paediatr. Child Health 14(1), 33-35 (2009).
3. White CP, Scott J. Meningococcal serogroup C conjugate vaccination in Canada: how far have we progressed? How far do we have to go? Can. J. Public Health. 101(1), 12-14 (2010).
4. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Members of Canadian Immunization Monitoring Program, Active (IMPACT). The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr. Infect. Dis. J. 32(1), e20-e25 (2013).
5. Dang V, Jamieson FB, Wilson S, et al. Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. BMC Infect. Dis. 12, 202 (2012).
6. Deeks S, Dang V, Jamieson F, Lim G, Rawte P, Crowcroft N. Estimating the number of infants needed to vaccinate to prevent a case of serogroup B invasive meningococcal disease. Presented at: European Scientific Conference on Applied Infectious Disease Epidemiology. Edinburgh, Scotland, UK, 24-26 October 2012.
7. British Columbia annual summary of reportable diseases. British Columbia Centre for Disease Control, Vancouver, 21-23 (2011).
8. Alberta health and wellness public health notifiable disease management guidelines meningococcal disease, Invasive (IMD). Alberta Health and Wellness, Edmonton, 3-9 (2011).
9. Zhou J, Lefebvre B, Deng S, et al. Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J. Clin. Microbiol. 50(5), 1545-1551 (2012).
10. Gilca R, Deceuninck G, Lefebvre B, et al. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. PLoS One 7(11), e50659 (2012).
11. Gottfredsson M, Reynisson IK, Ingvarsson RF, et al. Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin. Infect. Dis. 53(9), e117-e124 (2011).
12. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 106(5), 505-525 (1998).
13. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 27(Suppl. 2), B51-B63 (2009).
14. Halperin SA, Bettinger JA, Greenwood B et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 30(Suppl. 2), B26-B36 (2012).
15. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis. 44(5), 657-663 (2007).
16. Claus H, Maiden MC, Maag R, Frosch M, Vogel U. Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology (Reading, Engl.) 148(Part 6), 1813-1819 (2002).
17. Caugant DA, Maiden MC. Meningococcal carriage and disease-population biology and evolution. Vaccine 27(Suppl. 2), B64-B70 (2009).
18. Buckee CO, Jolley KA, Recker M, et al. Role of selection in the emergence of lineages and the evolution of virulence in Neisseria meningitidis. Proc. Natl Acad. Sci. USA 105(39), 15082-15087 (2008).
19. Harrison LH, Jolley KA, Shutt KA, et al.; Maryland Emerging Infections Program. Antigenic shift and increased incidence of meningococcal disease. J. Infect. Dis. 193(9), 1266-1274 (2006).
20. Tsang RS, Law DK, Henderson AM, Blake ML, Stoltz J. Increase in serogroup C meningococcal disease in Canada is associated with antigenic changes in the protein antigens of the ET-15 clone of Neisseria meningitidis. J. Infect. Dis. 194(12), 1791-1792; author reply 1792 (2006).
21. Hao W, Ma JH, Warren K, et al. Extensive genomic variation within clonal complexes of Neisseria meningitidis. Genome Biol. Evol. 3, 1406-1418 (2011).
22. Budroni S, Siena E, Dunning Hotopp JC et al. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc. Natl Acad. Sci. USA 108(11), 4494-4499 (2011).
23. Joseph B, Schwarz RF, Linke B, et al. Virulence evolution of the human pathogen Neisseria meningitidis by recombination in the core and accessory genome. PLoS One 6(4), e18441 (2011).
24. Joseph B, Schneiker-Bekel S, Schramm-Glück A, et al. Comparative genome biology of a serogroup B carriage and disease strain supports a polygenic nature of meningococcal virulence. J. Bacteriol. 192(20), 5363-5377 (2010).
25. Tsang RS, Law DK, Tyler SD, Stephens GS, Bigham M, Zollinger WD. Potential capsule switching from serogroup Y to B: the characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada. Can. J. Infect. Dis. Med. Microbiol. 16(3), 171-174 (2005).
26. Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J. Infect. Dis. 201(8), 1208-1224 (2010).
27. Castiñeiras TM, Barroso DE, Marsh JW et al. Capsular switching in invasive Neisseria meningitidis, Brazil(1). Emerging Infect. Dis. 18(8), 1336-1338 (2012).
28. Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect. Dis. 10, 175 (2010).
29. Tsang R. Capsule switching and capsule replacement in vaccine-preventable bacterial diseases. Lancet Infect. Dis. 7(9), 569-570 (2007).
30. Jamieson FB, Rawte P, Deeks SL, et al. Genetic and antigenic characterization of invasive endemic serogroup B Neisseria meningitidis from Ontario, Canada, in 2001-2010. J. Med. Microbiol. 62(Pt 1), 46-55 (2013).
31. De Wals P, Dionne M, Douville-Fradet M, Boulianne N, Drapeau J, De Serres G. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull. World Health Organ. 74(4), 407-411 (1996).
32. De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 292(20), 2491-2494 (2004).
33. Law DK, Lorange M, Ringuette L, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J. Clin. Microbiol. 44(8), 2743-2749 (2006).
34. Ashton FE, Ryan JA, Borczyk A, Caugant DA, Mancino L, Huang D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J. Clin. Microbiol. 29(11), 2489-2493 (1991).
35. Farley JD, Osei W. Invasive meningococcal disease, British Columbia. December 1991-March 1992. Can. J. Public Health. 83(2), 138-140 (1992).
36. Sweet L. The Prince Edward Island meningococcal immunization program. January-February 1992. Can. J. Public Health. 83(2), 129-130 (1992).
37. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 273(5), 383-389 (1995).
38. Jelfs J, Munro R, Ashto FE, Caugant DA. Genetic characterization of a new variant within the ET-37 complex of Neisseria meningitidis associated with outbreaks in various parts of the world. Epidemiol. Infect. 125(2), 285-298 (2000).
39. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2(8346), 355-357 (1983).
40. Jennings HJ, Roy R, Gamian A. Induction of meningococcal group B polysaccharidespecific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 137(5), 1708-1713 (1986).
41. Moe GR, Tan S, Granoff DM. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol. Med. Microbiol. 26(3-4), 209-226 (1999).
42. Howitz M, Krause TG, Simonsen JB, et al. Lack of association between group B meningococcal disease and autoimmune disease. Clin. Infect. Dis. 45(10), 1327-1334 (2007).
43. Robbins JB, Schneerson R, Xie G, Hanson LÅ, Åke-Hanson L, Miller MA. Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2. Proc. Natl Acad. Sci. USA 108(44), 17871-17875 (2011).
44. Bai X, Borrow R. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev. Vaccines 9(10), 1203-1217 (2010).
45. Granoff DM. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50 (Suppl. 2), S54-S65 (2010).
46. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103(29), 10834-10839 (2006).
47. Pillai S, Howell A, Alexander K, et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23(17-18), 2206-2209 (2005).
48. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51(10), 1127-1137 (2010).
49. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29(11), e71-e79 (2010).
50. Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum. Vaccin. 7(6), 646-653 (2011).
51. Gossger N, Snape MD, Yu LM, et al.; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307(6), 573-582 (2012).
52. Vesikari T, Esposito S, Prymula R, et al.; for the EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet doi:10.1016/S0140-6736(12)61961-8 (2013) (Epub ahead of print).
53. Vesikari T, Prymula R, Liese J, et al. Booster dose at 12 months of an investigational meningococcal serogroup B vaccine (4CMenB) in health toddlers previously primed at 2, 4, 6 months. Presented at: 29th European Society for Pediatric Infectious Disease (ESPID) Meeting. The Hague, The Netherlands, 7-11 June 2011.
54. Prymula R, Vesikari T, Esposito S, et al. Catch-up vaccination of health toddlers with an investigational multicomponent meningococcal serogroup B vaccine (4CMenB)-exploration of a two-dose schedule. Presented at: 29th European Society for Pediatric Infectious Disease (ESPID) Meeting. The Hague, The Netherlands, 7-11 June 2011.
55. Prymula R, Esposito S, Kittel C, Kohl I, Toneatto D, Dull P. Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunizations. Presented at: 29th European Society for Pediatric Infectious Disease (ESPID) Meeting. The Hague, The Netherlands, 7-11 June 2011.
56. Snape M, Robinson H, Kelly S, et al. Bactericidal antibody persistence two years following immunization with investigational serogroup B meningococcal vaccines at 6, 8, and 12 months and response to a booster dose in 40 month old children. Presented at: XVIII International Pathogenic Neisseria Conference. Würzburg, Germany, 9-14 September 2012.
57. Snape M, John T, Robinson H, et al. Persistence of bactericidal antibodies following early infant immunization with investigational serogroup B meningococcal vaccines and immunogenicity of pre-school booster doses. Presented at: XVIII International Pathogenic Neisseria Conference. Würzburg, Germany, 9-14 September 2012.
58. Martin N, Snape M, Robinson H, et al. Reactogenicity of investigational serogroup B meningococcal vaccines given at months of age to primed and vaccine naïve children. Presented at: XVIII International Pathogenic Neisseria Conference. Würzburg, Germany, 9-14 September 2012.
59. Santolaya ME, O'Ryan ML, Valenzuela MT, et al.; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a Phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379(9816), 617-624 (2012).
60. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin. Vaccine Immunol. 18(3), 483-486 (2011).
61. Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Borrow R. Safety and immunogenicity of a four component meningococcal B vaccine (4CMenB) and a quadrivalent meningococcal A, C, W135, and Y conjugate vaccine (Menveo) in UK laboratory workers with potential occupational exposure to meningococci. Presented at: XVIII International Pathogenic Neisseria Conference. Würzburg, Germany, 9-14 September 2012.
62. Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl Acad. Sci. USA 107(45), 19490-19495 (2010).
63. Bettinger JA, Scheifele DW, Halperin SA et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal sergroup B vaccine (4CMenB). Vaccine (2013) (In Press).
64. Richmond PC, Nissen MD, Marshall HS et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation Phase 1 trial. Vaccine 30(43), 6163-6174 (2012).
65. Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. A Phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum. Vaccin. Immunother. 8(7), 888-895 (2012).
66. Marshall HS, Richmond PC, Nissen MD et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a Phase 1 randomized-controlled clinical trial. Pediatr. Infect. Dis. J. 31(10), 1061-1068 (2012).
67. Richmond PC, Marshall HS, Nissen MD et al.; 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, Phase 2 trial. Lancet Infect. Dis. 12(8), 597-607 (2012).
68. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol. 53(Pt 9), 821-832 (2004).
69. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev. Vaccines 8(7), 851-861 (2009).
70. Fine PE. Herd immunity: history, theory, practice. Epidemiol. Rev. 15(2), 265-302 (1993).
71. Dellicour S, Greenwood B. Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop. Med. Int. Health 12(12), 1409-1421 (2007).
72. Maiden MC, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197(5), 737-743 (2008).
73. Maiden MC, Stuart JM; UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359(9320), 1829-1831 (2002).
74. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands. Pediatr. Infect. Dis. J. 25(1), 79-80 (2006).
75. Kinlin LM, Jamieson F, Brown EM, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 27(11), 1735-1740 (2009).
76. De Wals P. Meningococcal C vaccines: the Canadian experience. Pediatr. Infect. Dis. J. 23(Suppl. 12), S280-S284 (2004).
77. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13(9), 821-829 (1995).
78. Bjune G. 'Herd immunity' and the meningococcal vaccine trial in Norway. Lancet 340(8814), 315 (1992).
79. Perkins BA, Jonsdottir K, Briem H, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177(3), 683-691 (1998).
80. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 23(19), 2470-2476 (2005).
81. Christensen H, Trotter C, Hickman M, Edmunds W. Modelling the potential impact of meningococcal B vaccines in England. Presented at: Meningitis Research Foundation Conference. London, UK, November 2011.
82. Haines C. Parents' experiences of living through their child's suffering from and surviving severe meningococcal disease. Nurs. Crit. Care 10(2), 78-89 (2005).
83. Bedford H, Lansley M. More vaccines for children? Parents' views. Vaccine 25(45), 7818-7823 (2007).
84. Kempe A, Daley MF, McCauley MM, et al. Prevalence of parental concerns about childhood vaccines: the experience of primary care physicians. Am. J. Prev. Med. 40(5), 548-555 (2011).
85. Offit PA, Quarles J, Gerber MA, et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 109(1), 124-129 (2002).
86. Koslap-Petraco MB, Parsons T. Communicating the benefits of combination vaccines to parents and health care providers. J. Pediatr. Health Care 17(2), 53-57 (2003).
87. Le Saux N, Bettinger JA, Wootton S, et al. Profile of serogroup Y meningococcal infections in Canada: implications for vaccine selection. Can. J. Infect. Dis. Med. Microbiol. 20(4), e130-e134 (2009).
88. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr. Infect. Dis. J. 28(3), 220-224 (2009).
89. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 51(1), 228-235 (1995).
90. Riou JY, Guibourdenche M. Laboratory Methods, Neisseria and Branhamella. Institut Pasteur, Paris, France (1992).
91. Abdillahi H, Poolman JT. Whole cell ELISA for typing of Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett. 48, 367-371 (1987).
92. Selander RK, Caugant DA, Ochman H, Musser JM, Gilmour MN, Whittam TS. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. Appl. Environ. Microbiol. 51(5), 873-884 (1986).
93. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl Acad. Sci. USA 95(6), 3140-3145 (1998).
94. British Columbia Centre for Disease Control. Percent of two-year olds with up-to-date immunizations. www.bccdc.ca/NR/rdonlyres/B8FB94AC-A216-4AEF- B88A-5C3C539F2575/0/-public- report-2yearolds.pdf (Accessed 22 January 2013)
95. British Columbia Centre for Disease Control. Grade 6 students with up-to-date immunizations. www.bccdc.ca/default.htm (Accessed 22 January 2013)
96. Public Health Agency of Canada. Invasive meningococcal disease (IMD). www.phac-aspc.gc.ca/im/vpd-mev/meningococcal-eng.php (Accessed 27 September 2012)
97. ClinicalTrials.gov. Novartis Vaccine and Diagnostics Carriage Trial. http://clinicaltrials.gov/show/NCT01214850
98. Public Health Agency of Canada. Publicly funded Immunization Programs in Canada-Routine Schedule for Infants and Children including special programs and catch-up programs. www.phac-aspc.gc.ca/im/ptimprogprogimpt/table-1-eng.php (Accessed 1 November 2012)